CloudTop New Shine acquires Haisen Singapore company for over 1.7 billion RMB

SighingCashier · 2026-04-08T00:45:54+00:00

Cloud Top New Shine acquires HASTEN BIOPHARMACEUTICALS (SG), a subsidiary of Haisen Group, for $250 million. The company holds commercialization rights for 14 chronic disease products. This acquisition will strengthen Cloud Top New Shine's market presence and growth potential in the Asia-Pacific region.

SighingCashier

2026-04-08 00:45:54

Abstract generation in progress

Cloud Nine New Energy (01952) announced that, for a total consideration of US$250 million (approximately RMB 1.72B), it will acquire 100% of the equity interests in HASTEN BIOPHARMACEUTICALS (SG) under Haisen Group and assign the shareholder loans.

HASTEN BIOPHARMACEUTICALS (SG) mainly holds commercialization rights to 14 brand chronic disease products in multiple countries and regions across the Asia-Pacific region, and has established a pan-Asia-Pacific commercialization platform to serve a large and continuously growing group of chronic disease patients.

The directors of Cloud Nine New Energy believe that the acquisition is both strategically important and compelling from a commercial standpoint; it provides the Group with a ready-made regional platform, deepens the Group’s market positioning in relation to therapeutic-area-related markets, and enhances its synergistic ability to seize future growth opportunities in the Asia-Pacific region.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes